Phase 3 Readout
LBRX: Phase 3 Topline: A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Ef
October 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 1, 2027
- Company
- LB PHARMACEUTICALS INC (LBRX)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Ef
- Indication
- Schizophrenia